TIMP2 and fibrosarcoma: Taken together, these data provide evidence that the TIMP2-based recombinant protein LT endowed with binding capability to fibrosarcoma cells could serve as the carrier of targeting delivery, in addition, the enediyne-integrated analog LTE could act as a targeted agent.